Related references
Note: Only part of the references are listed.Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age
Javier Diez-Domingo et al.
JOURNAL OF INFECTIOUS DISEASES (2023)
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study
Megan Bardsley et al.
LANCET INFECTIOUS DISEASES (2023)
Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study
John DeVincenzo et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
Jerald Sadoff et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
RSV Vaccines, Finally Within Reach, Could Prevent Tens of Thousands of Yearly Deaths
Jennifer Abbasi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary
Shujing Xu et al.
MOLECULES (2022)
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge
Alaa Ahmad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States
William L. Herring et al.
VACCINE (2022)
Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
Nicolas Voirin et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy
Eric A. F. Simoes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Laura L. Hammitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
Susanna Esposito et al.
FRONTIERS IN IMMUNOLOGY (2022)
Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis
Sofia Tejada et al.
ADVANCES IN THERAPY (2022)
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
Alexia Kieffer et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
Kathrin Endt et al.
FRONTIERS IN IMMUNOLOGY (2022)
Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
Pardis Mokhtary et al.
BIOMEDICINES (2022)
Two competing RSV vaccines round final phase III corner
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2022)
Ribavirin Use in Hospitalized Children
William R. Otto et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2022)
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
Elke Jordan et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step
Marie-Noelle Billard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children
Ruth A. Karron et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Transient Neutropenia in Immunocompetent Infants with Respiratory Syncytial Virus Infection
Tatsuya Korematsu et al.
VIRUSES-BASEL (2021)
Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies
Harrison C. Bergeron et al.
VIRUSES-BASEL (2021)
The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review
Jing Shan et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2021)
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
Brian M. Maas et al.
EBIOMEDICINE (2021)
Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus In Vitro
Yuzhen Gao et al.
MOLECULES (2021)
EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model
Michael H. J. Rhodin et al.
PLOS PATHOGENS (2021)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Tracy J. Ruckwardt et al.
LANCET RESPIRATORY MEDICINE (2021)
Prevalence and Risk Factors of Respiratory Syncytial Virus in Children under 5 Years of Age in the WHO European Region: A Systematic Review and Meta-Analysis
Nora Suleiman-Martos et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020
Stefano Tempia et al.
Eurosurveillance (2021)
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Functional Features of the Respiratory Syncytial Virus G Protein
Larry J. Anderson et al.
VIRUSES-BASEL (2021)
Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection
Rosa Rodriguez-Fernandez et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2021)
Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies
Zifang Shang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection
Rosa Rodriguez-Fernandez et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2021)
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults
Antonios O. Aliprantis et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
Antonios O. Aliprantis et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults
Paola Cicconi et al.
CLINICAL INFECTIOUS DISEASES (2020)
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract
Francisco M. Marty et al.
CLINICAL INFECTIOUS DISEASES (2020)
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients
Roy F. Chemaly et al.
CLINICAL INFECTIOUS DISEASES (2020)
Respiratory Syncytial Virus Antivirals: Problems and Progress
Frederick G. Hayden et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV
Kirsten Stray et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children
Elizabeth J. McFarland et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
Nathaly Samy et al.
VACCINE (2020)
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection
Amy S. Espeseth et al.
NPJ VACCINES (2020)
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study
Federico Martinon-Torres et al.
CLINICAL INFECTIOUS DISEASES (2020)
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
Kristi Williams et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
Leslie van der Fits et al.
NPJ VACCINES (2020)
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial
Pauline Verdijk et al.
VACCINE (2020)
Emerging Concepts and Technologies in Vaccine Development
Morgan Brisse et al.
FRONTIERS IN IMMUNOLOGY (2020)
RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Oriol Manuel et al.
CLINICAL TRANSPLANTATION (2019)
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
Christopher A. Green et al.
JOURNAL OF INFECTION (2019)
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
Stephen Mac et al.
PEDIATRICS (2019)
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor
Xiufang Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
Aimin Tang et al.
NATURE COMMUNICATIONS (2019)
Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults
Xunyan Ye et al.
FRONTIERS IN IMMUNOLOGY (2019)
Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17
Bin Lu et al.
SCIENTIFIC REPORTS (2019)
Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice
Andri Vasou et al.
ANTIVIRAL RESEARCH (2018)
Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium
Daniel W. Brookes et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients
J. Gottlieb et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2018)
Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study
Marita Stevens et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
Joseph B. Domachowske et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
1335. Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
Lindsey Cass et al.
Open Forum Infectious Diseases (2018)
Respiratory Syncytial Virus Matrix (M) Protein Interacts with Actin In Vitro and in Cell Culture
Shadi Shahriari et al.
VIRUSES-BASEL (2018)
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations
Richard L. Wasserman et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Judith Falloon et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Exploiting virus-like particles as innovative vaccines against emerging viral infections
Hotcherl Jeong et al.
JOURNAL OF MICROBIOLOGY (2017)
Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells
B. Cortjens et al.
JOURNAL OF VIROLOGY (2017)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age
Allison August et al.
VACCINE (2017)
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Dirk Roymans et al.
NATURE COMMUNICATIONS (2017)
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
Iebe Rossey et al.
NATURE COMMUNICATIONS (2017)
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Louis Fries et al.
IMMUNITY & AGEING (2017)
Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases
Hyo-Jeong Lee et al.
PLOS ONE (2017)
Neutralizing epitopes of RSV and palivizumab resistance in Japan
Koichi Hashimoto et al.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (2017)
Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery
Elisabeth Heylen et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Laurent Detalle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
Patricio L. Acosta et al.
CLINICAL AND VACCINE IMMUNOLOGY (2016)
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
Gregory M. Glenn et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus
April M. Killikelly et al.
SCIENTIFIC REPORTS (2016)
Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection
Robert Jordan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells
Tatiana Chirkova et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study
Richard L. Mackman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
John P. DeVincenzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children
Ruth A. Karron et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein
Jason S. McLellan
CURRENT OPINION IN VIROLOGY (2015)
Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2′-Fluoro-4′-Chloromethyl-Cytidine Triphosphate
Jerome Deval et al.
PLOS PATHOGENS (2015)
RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets
Cory J. Knudson et al.
PLOS PATHOGENS (2015)
Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures
Sara M. Johnson et al.
PLOS PATHOGENS (2015)
Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604
SreeRupa Challa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner
Kwang-Il Jeong et al.
PLOS ONE (2015)
Social, economic, and health impact of the respiratory syncytial virus: a systematic search
Javier Diez-Domingo et al.
BMC INFECTIOUS DISEASES (2014)
Promoting Population Health through Financial Stewardship
Peter A. Ubel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
John P. DeVincenzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness
Octavio Ramilo et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus
Hans H. Hirsch et al.
CLINICAL INFECTIOUS DISEASES (2013)
Respiratory Syncytial Virus-A Comprehensive Review
Andrea T. Borchers et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2013)
The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid
Saskia E. Bakker et al.
JOURNAL OF GENERAL VIROLOGY (2013)
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
Davide Corti et al.
NATURE (2013)
Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants
Maarten O. Blanken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
Jason S. McLellan et al.
SCIENCE (2013)
Choosing Wisely Helping Physicians and Patients Make Smart Decisions About Their Care
Christine K. Cassel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Nonviral delivery of self-amplifying RNA vaccines
Andrew J. Geall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
Michael P. Frogel et al.
JOURNAL OF MANAGED CARE PHARMACY (2010)
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
John DeVincenzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
Rene Alvarez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
Ellen J. Collarini et al.
JOURNAL OF IMMUNOLOGY (2009)
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
Maria Florencia Delgado et al.
NATURE MEDICINE (2009)
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)
John DeVincenzo et al.
ANTIVIRAL RESEARCH (2008)
Function of the respiratory syncytial virus small hydrophobic protein
Sandra Fuentes et al.
JOURNAL OF VIROLOGY (2007)
Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children
K. Ventre et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2007)
Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy - a review
Yechiel Becker
VIRUS GENES (2006)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Unravelling the complexities of respiratory syncytial virus RNA synthesis
Vanessa M. Cowton et al.
JOURNAL OF GENERAL VIROLOGY (2006)
Inhibition of respiratory viruses by nasally administered siRNA
V Bitko et al.
NATURE MEDICINE (2005)
Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle
WV Kalina et al.
VACCINE (2004)
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection
X Sáez-Llorens et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
TF Feltes et al.
JOURNAL OF PEDIATRICS (2003)
A role for immune complexes in enhanced respiratory syncytial virus disease
FP Polack et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene
S Techaarpornkul et al.
JOURNAL OF VIROLOGY (2001)
Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection
RF Robinson et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2000)
Share Paper
